Citadel Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $19.4M | Buy |
1,118,715
+541,296
| +94% | +$7.42M | ﹤0.01% | 2635 |
|
|
2026
Q1 | $7.18M | Sell |
577,419
-5,598,318
| -91% | -$75.2M | ﹤0.01% | 3770 |
|
|
2025
Q4 | $77.8M | Buy |
6,175,737
+446,438
| +8% | +$5.11M | 0.01% | 1039 |
|
|
2025
Q3 | $57.4M | Buy |
5,729,299
+104,617
| +2% | +$939K | 0.01% | 1255 |
|
|
2025
Q2 | $45.5M | Sell |
5,624,682
-1,867,347
| -25% | -$14.1M | 0.01% | 1306 |
|
|
2025
Q1 | $62.8M | Sell |
7,492,029
-1,488,939
| -17% | -$12.4M | 0.01% | 983 |
|
|
2024
Q4 | $71.1M | Buy |
8,980,968
+88,675
| +1% | +$744K | 0.01% | 981 |
|
|
2024
Q3 | $74M | Sell |
8,892,293
-1,096,432
| -11% | -$8.57M | 0.01% | 920 |
|
|
2024
Q2 | $63.4M | Buy |
9,988,725
+4,921,242
| +97% | +$31.2M | 0.01% | 971 |
|
|
2024
Q1 | $30.7M | Sell |
5,067,483
-1,429,607
| -22% | -$8.06M | 0.01% | 1641 |
|
|
2023
Q4 | $39.4M | Buy |
6,497,090
+3,808,360
| +142% | +$17M | 0.01% | 1364 |
|
|
2023
Q3 | $11.3M | Buy |
2,688,730
+1,493,222
| +125% | +$5.57M | ﹤0.01% | 2528 |
|
|
2023
Q2 | $3.71M | Buy |
1,195,508
+160,305
| +15% | +$341K | ﹤0.01% | 4105 |
|
|
2023
Q1 | $1.44M | Buy |
1,035,203
+345,449
| +50% | +$688K | ﹤0.01% | 5993 |
|
|
2022
Q4 | $1.37M | Sell |
689,754
-956,839
| -58% | -$2.14M | ﹤0.01% | 6213 |
|
|
2022
Q3 | $3.33M | Buy |
1,646,593
+212,703
| +15% | +$596K | ﹤0.01% | 4595 |
|
|
2022
Q2 | $4.56M | Sell |
1,433,890
-31,230
| -2% | -$113K | ﹤0.01% | 3977 |
|
|
2022
Q1 | $6.11M | Sell |
1,465,120
-130,827
| -8% | -$579K | ﹤0.01% | 3796 |
|
|
2021
Q4 | $7.64M | Buy |
1,595,947
+435,040
| +37% | +$2.17M | ﹤0.01% | 3540 |
|
|
2021
Q3 | $6.2M | Buy |
1,160,907
+534,969
| +85% | +$2.69M | ﹤0.01% | 3906 |
|
|
2021
Q2 | $3.21M | Buy |
625,938
+5,423
| +0.9% | +$30.8K | ﹤0.01% | 5438 |
|
|
2021
Q1 | $4.18M | Sell |
620,515
-859,409
| -58% | -$4.76M | ﹤0.01% | 4671 |
|
|
2020
Q4 | $6.76M | Buy |
1,479,924
+172,597
| +13% | +$765K | ﹤0.01% | 3179 |
|
|
2020
Q3 | $5.07M | Buy |
1,307,327
+717,014
| +121% | +$3.07M | ﹤0.01% | 3137 |
|
|
2020
Q2 | $2.81M | Buy |
590,313
+238,737
| +68% | +$983K | ﹤0.01% | 3970 |
|
|
2020
Q1 | $1.22M | Sell |
351,576
-87,734
| -20% | -$372K | ﹤0.01% | 4964 |
|
|
2019
Q4 | $2.12M | Sell |
439,310
-210,945
| -32% | -$733K | ﹤0.01% | 4328 |
|
|
2019
Q3 | $1.89M | Buy |
650,255
+73,904
| +13% | +$258K | ﹤0.01% | 4562 |
|
|
2019
Q2 | $4.13M | Buy |
+576,351
| New | +$5.89M | ﹤0.01% | 3380 |
|
|
2018
Q3 | – | Sell |
-604,634
| Closed | -$12.7M | – | 9163 |
|
|
2018
Q2 | $9.92M | Buy |
+604,634
| New | +$10.6M | ﹤0.01% | 1939 |
|
Other funds holding AMRX
TGA
RCMNY
Citadel Advisors's AMRX Position: Q2 2026 in Review
Citadel Advisors increased its Amneal Pharmaceuticals (AMRX) stake by 94% in Q2 2026, buying an estimated $7.42M and bringing the position to 1,118,715 shares worth $19.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2635.
Citadel Advisors first reported a position in AMRX in Q2 2018 and has held it in 30 quarters since. The position peaked at $77.8M in Q4 2025. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.
- Citadel Advisors held 1,118,715 shares of Amneal Pharmaceuticals worth $19.4M as of Q2 2026.
- Citadel Advisors bought 541,296 Amneal Pharmaceuticals shares in Q2 2026, an estimated $7.42M.
- Amneal Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2635 holding.
- Citadel Advisors first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 30 quarters since.
- Citadel Advisors's Amneal Pharmaceuticals position peaked at $77.8M in Q4 2025.
- 311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.